Heat shock proteins: Therapeutic drug targets for chronic neurodegeneration?

Current Pharmaceutical Biotechnology

Volumn 11, Issue 2, 2010, Pages 198-215

  Sajjad, M U ^a   Samson, B ^a   Wyttenbach, A ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Molecular chaperones; Neuroprotection; Protein misfolding; Proteinopathies

Indexed keywords

2 CYCLOPENTEN 1 ONE; 3,4 DICHLOROISOCOUMARIN; ARIMOCLOMOL; CARBENOXOLONE; CELASTROL; CYCLOPENTENONE DERIVATIVE; GALLIUM NITRATE; GELDANAMYCIN; GLYCYRRHIZIC ACID; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 10; HEAT SHOCK PROTEIN 100; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HERBIMYCIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PAEONIFLORIN; POLAPREZINC; RADICICOL; REBAMIPIDE; SIMVASTATIN; SMALL HEAT SHOCK PROTEIN; TANESPIMYCIN; TEPRENONE; TOSYLLYSYL CHLOROMETHYL KETONE; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CHRONIC DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PROTEIN FOLDING; REVIEW;

ANIMALS; BRAIN; CHRONIC DISEASE; HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PRIONS; PROTEIN FOLDING;

EID: 77949877628     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110790909641     Document Type: Review

References (245)

1. Brouwers, N.; Sleegers, K.; Van Broeckhoven, C. Molecular genetics of Alzheimer's disease: an update. Ann. Med., 2008, 40(8), 562-583.
2. Albert, M. S. Cognitive and neurobiologic markers of early Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1996, 93(24), 13547-13551.
3. Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001,81(2), 741-766.
4. LaFerla, F. M.; Oddo, S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol. Med., 2005, 11(4), 170-176.
5. Grundke-Iqbal, I.; Iqbal, K.; Quinlan, M.; Tung, Y. C.; Zaidi, M. S.; Wisniewski, H. M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem., 1986, 261(13), 6084-6089.
6. Gendron, T. F.; Petrucelli, L. The role of tau in neurodegeneration. Mol. Neurodegener., 2009, 4(13), 1-19.
7. Dawson, T. M.; Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science, 2003, 302(5646), 819-822.
8. Gasser, T. Genomic and proteomic biomarkers for Parkinson disease. Neurology, 2009, 72(7 Suppl), S27-31.
9. Katsuno, M.; Adachi, H.; Waza, M.; Banno, H.; Suzuki, K.; Tanaka, F.; Doyu, M.; Sobue, G. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp. Neurol., 2006, 200(1), 8-18.
10. Zoghbi, H. Y.; Orr, H. T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci., 2000, 23, 217-247.
11. Vonsattel, J. P.; DiFiglia, M. Huntington disease. J. Neuropathol. Exp. Neurol., 1998, 57(5), 369-384.
12. Wong, P. C.; Rothstein, J. D.; Price, D. L. The genetic and molecular mechanisms of motor neuron disease. Curr. Opin. Neurobiol., 1998, 8(6), 791-799.
13. Van Damme, P.; Robberecht, W. Recent advances in motor neuron disease. Curr. Opin. Neurol., 1998, 22(5), 486-492.
14. Zhang, F.; Strom, A. L.; Fukada, K.; Lee, S.; Hayward, L. J.; Zhu, H. Interaction between familial amyotrophic lateral sclerosis (ALS)-linked SOD1 mutants and the dynein complex. J. Biol. Chem., 2007, 282(22), 16691-16699.
15. Bruijn, L. I.; Houseweart, M. K.; Kato, S.; Anderson, K. L.; Anderson, S. D.; Ohama, E.; Reaume, A. G.; Scott, R. W.; Cleveland, D. W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science, 1998, 281(5384), 1851-1854.
16. Prusiner, S. B. Molecular biology and genetics of neurodegenerative diseases caused by prions. Adv. Virus Res., 1992, 41, 241-280.
17. Mallucci, G.; Collinge, J. Update on Creutzfeldt-Jakob disease. Curr. Opin. Neurol., 2004, 17(6), 641-647.
18. Baker, H. F.; Ridley, R. M.; Wells, G. A.; Ironside, J. W. Prion protein immunohistochemical staining in the brains of monkeys with transmissible spongiform encephalopathy. Neuropathol. Appl. Neurobiol., 1998, 24(6), 476-486.
19. Tissieres, A.; Mitchell, H. K.; Tracy, U. M. Protein synthesis in salivary glands of Drosophila melanogaster: relation to chromosome puffs. J. Mol. Biol., 1974, 84(3), 389-398.
20. Feder, M. E.; Hofmann, G. E. Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology. Annu. Rev. Physiol., 1999, 61, 243-282.
21. Hayes, S. A.; Dice, J. F. Roles of molecular chaperones in protein degradation. J. Cell Biol., 1996, 132(3), 255-258.
22. Massey, A. C.; Zhang, C.; Cuervo, A. M. Chaperone-mediated autophagy in aging and disease. Curr. Top. Dev. Biol., 2006, 73, 205-235.
23. Quraishe, S.; Asuni, A.; Boelens, W. C.; O'Connor, V.; Wyttenbach, A. Expression of the small heat shock protein family in the mouse CNS: differential anatomical and biochemical compartmentalization. Neuroscience, 2008,153(2), 483-491.
24. Shashidharamurthy, R.; Koteiche, H. A.; Dong, J.; McHaourab, H. S. Mechanism of chaperone function in small heat shock proteins: dissociation of the HSP27 oligomer is required for recognition and binding of destabilized T4 lysozyme. J. Biol. Chem., 2005, 280(7), 5281-5289.
25. McHaourab, H. S.; Dodson, E. K.; Koteiche, H. A. Mechanism of chaperone function in small heat shock proteins. Two-mode binding of the excited states of T4 lysozyme mutants by alphaA-crystallin. J. Biol. Chem., 2002, 277(43), 40557-40566.
26. Koteiche, H. A.; McHaourab, H. S. Mechanism of chaperone function in small heat-shock proteins. Phosphorylation-induced activation of two-mode binding in alphaB-crystallin. J. Biol. Chem., 2003, 278(12), 10361-10367.
27. Horwitz, J. The function of alpha-crystallin in vision. Semin. Cell Dev. Biol., 2000, 11(1), 53-60.
28. Cashikar, A. G.; Duennwald, M.; Lindquist, S. L. A chaperone pathway in protein disaggregation. Hsp26 alters the nature of protein aggregates to facilitate reactivation by Hsp104. J. Biol. Chem., 2005, 280(25), 23869-23875.
29. Kim, K. K.; Kim, R.; Kim, S. H. Crystal structure of a small heat-shock protein. Nature, 1998, 394(6693), 595-599.
30. van Montfort, R. L.; Basha, E.; Friedrich, K. L.; Slingsby, C.; Vierling, E. Crystal structure and assembly of a eukaryotic small heat shock protein. Nat. Struct. Biol., 2001, 8(12), 1025-1030.
31. Sun, Y.; MacRae, T. H. The small heat shock proteins and their role in human disease. FEBS J., 2005, 272(11), 2613-2627.
32. Haslbeck, M.; Franzmann, T.; Weinfurtner, D.; Buchner, J. Some like it hot: the structure and function of small heat-shock proteins. Nat. Struct. Mol. Biol., 2005, 12(10), 842-846.
33. Bukau, B.; Horwich, A. L. The Hsp70 and Hsp60 chaperone machines. Cell, 1998, 92(3), 351-366.
34. Richardson, A.; Landry, S. J.; Georgopoulos, C. S. The ins and outs of a molecular chaperone machines. Trends Biochem. Sci., 1998, 23(4), 138-143.
35. Soltys, B. J.; Gupta, R. S. Immunoelectron microscopic localization of the 60-kDa heat shock chaperonin protein (Hsp60) in mammalian cells. Exp. Cell Res., 1996, 222(1), 16-27.
36. Hansen, J. J.; Durr, A.; Cournu-Rebeix, I.; Georgopoulos, C.; Ang, D.; Nielsen, M. N.; Davoine, C. S.; Brice, A.; Fontaine, B.; Gregersen, N.; Bross, P. Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am. J. Hum. Genet., 2002,70(5), 1328-1332.
37. Hansen, J.; Svenstrup, K.; Ang, D.; Nielsen, M. N.; Christensen, J. H.; Gregersen, N.; Nielsen, J. E.; Georgopoulos, C.; Bross, P. A novel mutation in the HSPD1 gene in a patient with hereditary spastic paraplegia. J. Neurol., 2007, 254(7), 897-900.
38. Magen, D.; Georgopoulos, C.; Bross, P.; Ang, D.; Segev, Y.; Goldsher, D.; Nemirovski, A.; Shahar, E.; Ravid, S.; Luder, A.; Heno, B.; Gershoni-Baruch, R.; Skorecki, K.; Mandel, H. Mitochondrial hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. Am. J. Hum. Genet., 2008, 83(1), 30-42.
39. Csermely, P.; Schnaider, T.; Soti, C.; Prohaszka, Z.; Nardai, G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther., 1998, 79(2), 129-168.
40. Felts, S. J.; Owen, B. A.; Nguyen, P.; Trepel, J.; Donner, D. B.; Toft, D. O. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J. Biol. Chem., 2000, 275(5), 3305-3312.
41. Pratt, W. B.; Toft, D. O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood)., 2003, 228(2), 111-133.
42. Sullivan, W.; Stensgard, B.; Caucutt, G.; Bartha, B.; McMahon, N.; Alnemri, E. S.; Litwack, G.; Toft, D. Nucleotides and two functional states of hsp90. J. Biol. Chem., 1997, 272(12), 8007-8012.
43. Waza, M.; Adachi, H.; Katsuno, M.; Minamiyama, M.; Tanaka, F.; Doyu, M.; Sobue, G. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J. Mol. Med., 2006, 84(8), 635-646.
44. Neckers, L.; Neckers, K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin. Emerg. Drugs, 2005, 10(1), 137-149.
45. Egorin, M. J.; Zuhowski, E. G.; Rosen, D. M.; Sentz, D. L.; Covey, J. M.; Eiseman, J. L. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother. Pharmacol., 2001, 47(4), 291-302.
46. McClellan, A. J.; Tam, S.; Kaganovich, D.; Frydman, J. Protein quality control: chaperones culling corrupt conformations. Nat. Cell Biol., 2005, 7(8), 736-741.
47. Cheetham, M. E.; Caplan, A. J. Structure, function and evolution of DnaJ: conservation and adaptation of chaperone function. Cell Stress Chaperone, 1998, 3(1), 28-36.
48. Meacham, G. C.; Lu, Z.; King, S.; Sorscher, E.; Tousson, A.; Cyr, D. M. The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J., 1999, 18(6), 1492-1505.
49. Sreedhar, A. S.; Kalmar, E.; Csermely, P.; Shen, Y. F. Hsp90 isoforms: functions, expression and clinical importance FEBS Lett., 2004, 562(1-3), 11-15.
50. Fan, C. Y.; Lee, S.; Cyr, D. M. Mechanisms for regulation of Hsp70 function by Hsp40. Cell Stress Chaperones., 2003, 8(4), 309-316.
51. Maurizi, M.R.; Xia, D. Protein binding and disruption by Clp/Hsp100 chaperones. Structure, 2004, 12(2), 175-183.
52. Ammelburg, M.; Frickey, T.; Lupas, A. N. Classification of AAA+ proteins. J. Struct. Biol., 2006, 156(1), 2-11.
53. Pratt, W. B.; Toft, D. O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood), 2003, 228(2), 111-133.
54. Soti, C.; Nagy, E.; Giricz, Z.; Vigh, L.; Csermely, P.; Ferdinandy, P. Heat shock proteins as emerging therapeutic targets. Br. J. Pharmacol., 2005, 146(6), 769-780.
55. Sreedhar, A. S.; Kalmar, E.; Csermely, P.; Shen, Y. F. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett., 2004, 562(1-3), 11-15.
56. Pearl, L. H.; Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem., 2006, 75, 271-294.
57. Chiosis, G.; Vilenchik, M.; Kim, J.; Solit, D. Hsp90: the vulnerable chaperone. Drug Discov. Today, 2004, 9(20), 881-888.
58. Ben-Zvi, A. P.; Goloubinoff, P. Mechanisms of disaggregation and refolding of stable protein aggregates by molecular chaperones. J. Struct. Biol., 2001, 135(2), 84-93.
59. Horwich, A. L.; Weber-Ban, E. U.; Finley, D. Chaperone rings in protein folding and degradation. Proc. Natl. Acad. Sci. USA, 1999, 96(20), 11033-11040.
60. Lee-Yoon, D.; Easton, D.; Murawski, M.; Burd, R.; Subjeck, J. R. Identification of a major subfamily of large hsp70-like proteins through the cloning of the mammalian 110-kDa heat shock protein. J. Biol. Chem., 1995, 270(26), 15725-15733.
61. Easton, D. P.; Kaneko, Y.; Subjeck, J. R. The hsp110 and Grp1 70 stress proteins: newly recognized relatives of the Hsp70s. Cell Stress Chaperones., 2000, 5(4), 276-290.
62. Hylander, B. L.; Chen, X.; Graf, P. C.; Subjeck, J. R. The distribution and localization of hsp110 in brain. Brain Res., 2000, 869(1-2), 49-55.
63. Polier, S.; Dragovic, Z.; Hartl, F. U.; Bracher, A. Structural basis for the cooperation of Hsp70 and Hsp110 chaperones in protein folding. Cell, 2008, 133(6), 1068-1079.
64. Yamashita, H.; Kawamata, J.; Okawa, K.; Kanki, R.; Nakamizo, T.; Hatayama, T.; Yamanaka, K.; Takahashi, R.; Shimohama, S. Heat-shock protein 105 interacts with and suppresses aggregation of mutant Cu/Zn superoxide dismutase: clues to a possible strategy for treating ALS. J. Neurochem., 2007, 102(5), 1497-1505.
65. Wang, J.; Farr, G. W.; Zeiss, C. J.; Rodriguez-Gil, D. J.; Wilson, J. H.; Furtak, K.; Rutkowski, D. T.; Kaufman, R. J.; Ruse, C. I.; Yates, J. R., 3rd; Perrin, S.; Feany, M. B.; Horwich, A. L. Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS. Proc. Natl. Acad. Sci. USA, 2009, 106(5), 1392-1397.
66. Wang, Q.; Bag, J. Induction of expression and co-localization of heat shock polypeptides with the polyalanine expansion mutant of poly(A)-binding protein N1 after chemical stress. Biochem. Biophys. Res. Commun., 2008, 370(1), 11-15.
67. McLean, P. J.; Kawamata, H.; Shariff, S.; Hewett, J.; Sharma, N.; Ueda, K.; Breakefield, X. O.; Hyman, B. T. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J. Neurochem., 2002, 83(4), 846-854.
68. Rubinsztein, D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature, 2006, 443(7113), 780-786.
69. Carra, S.; Seguin, S. J.; Lambert, H.; Landry, J. HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. J. Biol. Chem., 2008, 283(3), 1437-1444.
70. Parcellier, A.; Schmitt, E.; Gurbuxani, S.; Seigneurin-Berny, D.; Pance, A.; Chantome, A.; Plenchette, S.; Khochbin, S.; Solary, E.; Garrido, C. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol. Cell. Biol., 2003, 23(16), 5790-5802.
71. Firdaus, W. J.; Wyttenbach, A.; Diaz-Latoud, C.; Currie, R. W.; Arrigo, A. P. Analysis of oxidative events induced by expanded polyglutamine huntingtin exon 1 that are differentially restored by expression of heat shock proteins or treatment with an antioxidant. FEBS J., 2006, 273(13), 3076-3093.
72. Shimura, H.; Miura-Shimura, Y.; Kosik, K. S. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J. Biol. Chem., 2004, 279(17), 17957-17962.
73. Wilhelmus, M. M.; Boelens, W. C.; Otte-Holler, I.; Kamps, B.; de Waal, R. M.; Verbeek, M. M. Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. Brain Res., 2006, 1089(1), 67-78.
74. Wyttenbach, A. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis. J. Mol. Neurosci., 2004, 23(1-2), 69-96.
75. Wyttenbach, A.; Sauvageot, O.; Carmichael, J.; Diaz-Latoud, C.; Arrigo, A. P.; Rubinsztein, D. C. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet., 2002, 11(9), 1137-1151.
76. Ousman, S. S.; Tomooka, B. H.; van Noort, J. M.; Wawrousek, E. F.; O'Connor, K. C.; Hafler, D. A.; Sobel, R. A.; Robinson, W. H.; Steinman, L. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature, 2007, 448(7152), 474-479.
77. Head, M. W.; Goldman, J. E. Small heat shock proteins, the cytoskeleton, and inclusion body formation. Neuropathol. Appl. Neurobiol., 2000, 26(4), 304-312.
78. Kato, K.; Inaguma, Y.; Ito, H.; Iida, K.; Iwamoto, I.; Kamei, K.; Ochi, N.; Ohta, H.; Kishikawa, M. Ser-59 is the major phosphorylation site in alphaB-crystallin accumulated in the brains of patients with Alexander's disease. J. Neurochem., 2001, 76(3), 730-736.
79. Iwaki, A.; Iwaki, T.; Goldman, J. E.; Ogomori, K.; Tateishi, J.; Sakaki, Y. Accumulation of alpha B-crystallin in brains of patients with Alexander's disease is not due to an abnormality of the 5′-flanking and coding sequence of the genomic DNA. Neurosci. Lett., 1992, 140(1), 89-92.
80. Iwaki, T.; Wisniewski, T.; Iwaki, A.; Corbin, E.; Tomokane, N.; Tateishi, J.; Goldman, J. E. Accumulation of alpha B-crystallin in central nervous system glia and neurons in pathologic conditions. Am. J. Pathol., 1992, 140(2), 345-356.
81. Renkawek, K.; de Jong, W. W.; Merck, K. B.; Frenken, C. W.; van Workum, F. P.; Bosman, G. J. alpha B-crystallin is present in reactive glia in Creutzfeldt-Jakob disease. Acta Neuropathol., 1992, 83(3), 324-327.
82. Irobi, J.; Van Impe, K.; Seeman, P.; Jordanova, A.; Dierick, I.; Verpoorten, N.; Michalik, A.; De Vriendt, E.; Jacobs, A.; Van Gerwen, V.; Vennekens, K.; Mazanec, R.; Tournev, I.; Hilton-Jones, D.; Talbot, K.; Kremensky, I.; Van Den Bosch, L.; Robberecht, W.; Van Vandekerckhove, J.; Van Broeckhoven, C.; Gettemans, J.; De Jonghe, P.; Timmerman, V. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat. Genet., 2004, 36(6), 597-601.
83. Evgrafov, O. V.; Mersiyanova, I.; Irobi, J.; Van Den Bosch, L.; Dierick, I.; Leung, C. L.; Schagina, O.; Verpoorten, N.; Van Impe, K.; Fedotov, V.; Dadali, E.; Auer-Grumbach, M.; Windpassinger, C.; Wagner, K.; Mitrovic, Z.; Hilton-Jones, D.; Talbot, K.; Martin, J. J.; Vasserman, N.; Tverskaya, S.; Polyakov, A.; Liem, R. K.; Gettemans, J.; Robberecht, W.; De Jonghe, P.; Timmerman, V. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat. Genet., 2004, 36(6), 602-606.
84. Houlden, H.; Laura, M.; Wavrant-De Vrieze, F.; Blake, J.; Wood, N.; Reilly, M. M. Mutations in the HSP27 (HSPB1) gene cause dominant, recessive, and sporadic distal HMN/CMT type 2. Neurology, 2008, 71(21), 1660-1668.
85. Fontaine, J. M.; Sun, X.; Hoppe, A. D.; Simon, S.; Vicart, P.; Welsh, M. J.; Benndorf, R. Abnormal small heat shock protein interactions involving neuropathy-associated HSP22 (HSPB8) mutants. FASEB J., 2006, 20(12), 2168-2170.
86. Zhai, J.; Lin, H.; Julien, J. P.; Schlaepfer, W. W. Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot-Marie-Tooth disease-linked mutations in NFL and HSPB1. Hum. Mol. Genet., 2007, 16(24), 3103-3116.
87. Zourlidou, A.; Gidalevitz, T.; Kristiansen, M.; Landles, C.; Woodman, B.; Wells, D. J.; Latchman, D. S.; de Belleroche, J.; Tabrizi, S. J.; Morimoto, R. I.; Bates, G. P. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation. Hum. Mol. Genet., 2007, 16(9), 1078-1090.
88. Wu, S. C.; Shiang, J. C.; Lin, S. L.; Wu, T. L.; Huang, W. C.; Chiou, K. R.; Liu, C. P. Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins. Heart Vessels, 2005, 20(5), 217-223.
89. Palinski, W. Immunomodulation: a new role for statins? Nat. Med., 2000, 6(12), 1311-1312.
90. Erl, W. Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis? Curr. Drug Targets Cardiovasc. Haematol. Disord., 2005, 5(2), 135-144.
91. Laufs, U.; Endres, M.; Custodis, F.; Gertz, K.; Nickenig, G.; Liao, J. K.; Bohm, M. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation, 2000, 102(25), 3104-3110.
92. Wang, X.; Tokuda, H.; Hatakeyama, D.; Hirade, K.; Niwa, M.; Ito, H.; Kato, K.; Kozawa, O. Mechanism of simvastatin on induction of heat shock protein in osteoblasts. Arch. Biochem. Biophys., 2003, 415(1), 6-13.
93. Uchiyama, T.; Atsuta, H.; Utsugi, T.; Oguri, M.; Hasegawa, A.; Nakamura, T.; Nakai, A.; Nakata, M.; Maruyama, I.; Tomura, H.; Okajima, F.; Tomono, S.; Kawazu, S.; Nagai, R.; Kurabayashi, M. HSF1 and constitutively active HSF1 improve vascular endothelial function (heat shock proteins improve vascular endothelial function). Atherosclerosis, 2007, 190(2), 321-329.
94. Kretz, A.; Schmeer, C.; Tausch, S.; Isenmann, S. Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Neurobiol. Dis., 2006, 21(2), 421-430.
95. Schmeer, C.; Gamez, A.; Tausch, S.; Witte, O. W.; Isenmann, S. Statins modulate heat shock protein expression and enhance retinal ganglion cell survival after transient retinal ischemia/reperfusion in vivo. Invest. Ophthalmol. Vis. Sci., 2008, 49(11), 4971-4981.
96. Wolozin, B. A fluid connection: cholesterol and Abeta. Proc. Natl. Acad. Sci. USA, 2001, 98(10), 5371-5373.
97. Li, G.; Higdon, R.; Kukull, W. A.; Peskind, E.; Van Valen Moore, K.; Tsuang, D.; van Belle, G.; McCormick, W.; Bowen, J. D.; Teri, L.; Schellenberg, G. D.; Larson, E. B. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology, 2004, 63(9), 1624-1628.
98. Fassbender, K.; Simons, M.; Bergmann, C.; Stroick, M.; Lutjohann, D.; Keller, P.; Runz, H.; Kuhl, S.; Bertsch, T.; von Bergmann, K.; Hennerici, M.; Beyreuther, K.; Hartmann, T. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 2001, 98(10), 5856-5861.
99. Boimel, M.; Grigoriadis, N.; Lourbopoulos, A.; Touloumi, O.; Rosenmann, D.; Abramsky, O.; Rosenmann, H. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol., 2009, 68(3), 314-325.
100. Wolozin, B.; Wang, S. W.; Li, N. C.; Lee, A.; Lee, T. A.; Kazis, L. E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med., 2007, 5, 20.
101. Mutez, E.; Duhamel, A.; Defebvre, L.; Bordet, R.; Destee, A.; Kreisler, A. Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease. Pharmacol. Res., 2009, 60(1), 41-45.
102. Mok, S. W.; Thelen, K. M.; Riemer, C.; Bamme, T.; Gultner, S.; Lutjohann, D.; Baier, M. Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem. Biophys. Res. Commun., 2006, 348(2), 697-702.
103. Kempster, S.; Bate, C.; Williams, A. Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport, 2007, 18(5), 479-482.
104. Haviv, Y.; Avrahami, D.; Ovadia, H.; Ben-Hur, T.; Gabizon, R.; Sharon, R. Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin. Arch. Neurol., 2008, 65(6), 762-775.
105. Bate, C.; Tayebi, M.; Diomede, L.; Salmona, M.; Williams, A. Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells. BMC Biol., 2008, 6, 39.
106. Drory, V. E.; Bronipolsky, T.; Artamonov, I.; Nefussy, B. Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J. Neurol. Sci., 2008, 273(1-2), 81-83.
107. Yan, D.; Saito, K.; Ohmi, Y.; Fujie, N.; Ohtsuka, K. Paeoniflorin, a novel heat shock protein-inducing compound. Cell Stress Chaperone., 2004, 9(4), 378-389.
108. Wang, Z.; Gao, R.; Huang, Y.; Tian, B.; Zhou, Y. Effects of mitogen-activated protein kinase signal pathway on heat shock protein 27 expression in human lens epithelial cells exposed to sodium salicylate in vitro. J. Huazhong Univ. Sci. Technolog. Med. Sci., 2009, 29(3), 377-382.
109. Lee, B. S.; Chen, J.; Angelidis, C.; Jurivich, D. A.; Morimoto, R. I. Pharmacological modulation of heat shock factor 1 by antiinflammatory drugs results in protection against stress-induced cellular damage. Proc. Natl. Acad. Sci. USA, 1995, 92(16), 7207-7211.
110. Amici, C.; Rossi, A.; Santoro, M. G. Aspirin enhances thermotolerance in human erythroleukemic cells: an effect associated with the modulation of the heat shock response. Cancer Res., 1995, 55(19), 4452-4457.
111. Jurivich, D. A.; Sistonen, L.; Sarge, K. D.; Morimoto, R. I. Arachidonate is a potent modulator of human heat shock gene transcription. Proc. Natl. Acad. Sci. USA, 1994, 91(6), 2280-2284.
112. Kato, K.; Ito, H.; Kamei, K.; Iwamoto, I. Stimulation of the stress-induced expression of stress proteins by curcumin in cultured cells and in rat tissues in vivo. Cell Stress Chaperone., 1998, 3(3), 152-160.
113. Ohta, H.; Ni, J. W.; Matsumoto, K.; Watanabe, H.; Shimizu, M. Peony and its major constituent, paeoniflorin, improve radial maze performance impaired by scopolamine in rats. Pharmacol. Biochem. Behav., 1993, 45(3), 719-723.
114. Okubo, T.; Nagai, F.; Seto, T.; Satoh, K.; Ushiyama, K.; Kano, I. The inhibition of phenylhydroquinone-induced oxidative DNA cleavage by constituents of Moutan Cortex and Paeoniae Radix. Biol. Pharm. Bull., 2000, 23(2), 199-203.
115. Pompei, R.; Flore, O.; Marccialis, M. A.; Pani, A.; Loddo, B. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature, 1979, 281(5733), 689-690.
116. Park, H. Y.; Park, S. H.; Yoon, H. K.; Han, M. J.; Kim, D. H. Antiallergic activity of 18beta-glycyrrhetinic acid-3-O-beta-D-glucuronide. Arch. Pharm. Res., 2004, 27(1), 57-60.
117. Inoue, H.; Mori, T.; Shibata, S.; Koshihara, Y. Modulation by glycyrrhetinic acid derivatives of TPA-induced mouse ear oedema. Br. J. Pharmacol., 1989, 96(1), 204-210.
118. Zhong, S. Z.; Ge, Q. H.; Li, Q.; Qu, R.; Ma, S. P. Peoniflorin attentuates Abeta((1-42))-mediated neurotoxicity by regulating calcium homeostasis and ameliorating oxidative stress in hippocampus of rats. J. Neurol. Sci., 2009, 280(1-2), 71-78.
119. Muchowski, P. J.; Schaffar, G.; Sittler, A.; Wanker, E. E.; Hayer-Hartl, M. K.; Hartl, F. U. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. USA, 2000, 97(14), 7841-7846.
120. Wacker, J. L.; Zareie, M. H.; Fong, H.; Sarikaya, M.; Muchowski, P. J. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat. Struct. Mol. Biol., 2004, 11(12), 1215-1222.
121. Evans, C. G.; Wisen, S.; Gestwicki, J. E. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J. Biol. Chem., 2006, 281(44), 33182-33191.
122. Chai, Y.; Koppenhafer, S. L.; Bonini, N. M.; Paulson, H. L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci., 1999, 19(23), 10338-10347.
123. Goswami, A.; Dikshit, P.; Mishra, A.; Mulherkar, S.; Nukina, N.; Jana, N. R. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem. Biophys. Res. Commun., 2006, 342(1), 184-190.
124. Wyttenbach, A.; Carmichael, J.; Swartz, J.; Furlong, R. A.; Narain, Y.; Rankin, J.; Rubinsztein, D. C. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA, 2000, 97(6), 2898-2903.
125. Wyttenbach, A.; Swartz, J.; Kita, H.; Thykjaer, T.; Carmichael, J.; Bradley, J.; Brown, R.; Maxwell, M.; Schapira, A.; Orntoft, T. F.; Kato, K. Rubinsztein, D. C. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet., 2001, 10(17), 1829-1845.
126. McNaught, K. S.; Shashidharan, P.; Perl, D. P.; Jenner, P.; Olanow, C. W. Aggresome-related biogenesis of Lewy bodies. Eur. J. Neurosci., 2002, 16(11), 2136-2148.
127. Fonte, V.; Kapulkin, V.; Taft, A.; Fluet, A.; Friedman, D.; Link, C. D. Interaction of intracellular beta amyloid peptide with chaperone proteins. Proc. Natl. Acad. Sci. USA, 2002, 99(14), 9439-9444.
128. Muchowski, P. J.; Wacker, J. L. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci., 2005, 6(1), 11-22.
129. Magrane, J.; Smith, R. C.; Walsh, K.; Querfurth, H. W. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J. Neurosci., 2004, 24(7), 1700-1706.
130. Bruening, W.; Roy, J.; Giasson, B.; Figlewicz, D. A.; Mushynski, W. E.; Durham, H. D. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J. Neurochem., 1999, 72(2), 693-699.
131. Cummings, C. J.; Sun, Y.; Opal, P.; Antalffy, B.; Mestril, R.; Orr, H. T.; Dillmann, W. H.; Zoghbi, H. Y. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum. Mol. Genet., 2001, 10(14), 1511-1518.
132. Warrick, J. M.; Chan, H. Y.; Gray-Board, G. L.; Chai, Y.; Paulson, H. L.; Bonini, N. M. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet., 1999, 23(4), 425-428.
133. Adachi, H.; Katsuno, M.; Minamiyama, M.; Sang, C.; Pagoulatos, G.; Angelidis, C.; Kusakabe, M.; Yoshiki, A.; Kobayashi, Y.; Doyu, M.; Sobue, G. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J. Neurosci., 2003, 23(6), 2203-2211.
134. Dong, Z.; Wolfer, D. P.; Lipp, H. P.; Bueler, H. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol. Ther., 2005, 11(1), 80-88.
135. Klucken, J.; Shin, Y.; Masliah, E.; Hyman, B. T.; McLean, P. J. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J. Biol. Chem., 2004, 279(24), 25497-25502.
136. Wacker, J. L.; Huang, S. Y.; Steele, A. D.; Aron, R.; Lotz, G. P.; Nguyen, Q.; Giorgini, F.; Roberson, E. D.; Lindquist, S.; Masliah, E.; Muchowski, P. J. Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. J. Neurosci., 2009, 29(28), 9104-9114.
137. Gifondorwa, D. J.; Robinson, M. B.; Hayes, C. D.; Taylor, A. R.; Prevette, D. M.; Oppenheim, R. W.; Caress, J.; Milligan, C. E. Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model of amyotrophic lateral sclerosis. J. Neurosci., 2007, 27(48), 13173-13180.
138. Hirakawa, T.; Rokutan, K.; Nikawa, T.; Kishi, K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology, 1996, 111(2), 345-357.
139. Ooie, T.; Takahashi, N.; Saikawa, T.; Nawata, T.; Arikawa, M.; Yamanaka, K.; Hara, M.; Shimada, T.; Sakata, T. Single oral dose of geranylgeranylacetone induces heat-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation, 2001, 104(15), 1837-1843.
140. Yamagami, K.; Yamamoto, Y.; Ishikawa, Y.; Yonezawa, K.; Toyokuni, S.; Yamaoka, Y. Effects of geranyl-geranyl-acetone administration before heat shock preconditioning for conferring tolerance against ischemia-reperfusion injury in rat livers. J. Lab. Clin. Med., 2000, 135(6), 465-475.
141. Mikuriya, T.; Sugahara, K.; Sugimoto, K.; Fujimoto, M.; Takemoto, T.; Hashimoto, M.; Hirose, Y.; Shimogori, H.; Hayashida, N.; Inouye, S.; Nakai, A.; Yamashita, H. Attenuation of progressive hearing loss in a model of age-related hearing loss by a heat shock protein inducer, geranylgeranylacetone. Brain Res., 2008, 1212, 9-17.
142. Mikuriya, T.; Sugahara, K.; Takemoto, T.; Tanaka, K.; Takeno, K.; Shimogori, H.; Nakai, A.; Yamashita, H. Geranylgeranylacetone, a heat shock protein inducer, prevents acoustic injury in the guinea pig. Brain Res., 2005, 1065(1-2), 107-114.
143. Sinn, D. I.; Chu, K.; Lee, S. T.; Song, E. C.; Jung, K. H.; Kim, E. H.; Park, D. K.; Kang, K. M.; Kim, M.; Roh, J. K. Pharmacological induction of heat shock protein exerts neuroprotective effects in experimental intracerebral hemorrhage. Brain Res., 2007, 1135(1), 167-176.
144. Fujiki, M.; Hikawa, T.; Abe, T.; Uchida, S.; Morishige, M.; Sugita, K.; Kobayashi, H. Role of protein kinase C in neuroprotective effect of geranylgeranylacetone, a noninvasive inducing agent of heat shock protein, on delayed neuronal death caused by transient ischemia in rats. J. Neurotrauma, 2006, 23(7), 1164-1178.
145. Uchida, S.; Fujiki, M.; Nagai, Y.; Abe, T.; Kobayashi, H. Geranylgeranylacetone, a noninvasive heat shock protein inducer, induces protein kinase C and leads to neuroprotection against cerebral infarction in rats. Neurosci. Lett., 2006, 396(3), 220-224.
146. Katsuno, M.; Sang, C.; Adachi, H.; Minamiyama, M.; Waza, M.; Tanaka, F.; Doyu, M.; Sobue, G. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc. Natl. Acad. Sci. USA, 2005, 102(46), 16801-16806.
147. Vigh, L.; Literati, P. N.; Horvath, I.; Torok, Z.; Balogh, G.; Glatz, A.; Kovacs, E.; Boros, I.; Ferdinandy, P.; Farkas, B.; Jaszlits, L.; Jednakovits, A.; Koranyi, L.; Maresca, B. Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nat. Med., 1997, 3(10), 1150-1154.
148. Batulan, Z.; Shinder, G. A.; Minotti, S.; He, B. P.; Doroudchi, M. M.; Nalbantoglu, J.; Strong, M. J.; Durham, H. D. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. J. Neurosci., 2003, 23(13), 5789-5798.
149. Kieran, D.; Kalmar, B.; Dick, J. R.; Riddoch-Contreras, J.; Burnstock, G.; Greensmith, L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med., 2004, 10(4), 402-405.
150. Kalmar, B.; Novoselov, S.; Gray, A.; Cheetham, M. E.; Margulis, B.; Greensmith, L. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J. Neurochem., 2008, 107(2), 339-350.
151. Allison, A. C.; Cacabelos, R.; Lombardi, V. R.; Alvarez, X. A.; Vigo, C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2001, 25(7), 1341-1357.
152. Brinker, A. M.; Ma, J.; Lipsky, P. E.; Raskin, I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry, 2007, 68(6), 732-766.
153. Westerheide, S. D.; Bosman, J. D.; Mbadugha, B. N.; Kawahara, T. L.; Matsumoto, G.; Kim, S.; Gu, W.; Devlin, J. P.; Silverman, R. B.; Morimoto, R. I. Celastrols as inducers of the heat shock response and cytoprotection. J. Biol. Chem., 2004, 279(53), 56053-56060.
154. Zhang, Y. Q.; Sarge, K. D. Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response. J. Mol. Med., 2007, 85(12), 1421-1428.
155. Cleren, C.; Calingasan, N. Y.; Chen, J.; Beal, M. F. Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J. Neurochem., 2005, 94(4), 995-1004.
156. Kiaei, M.; Kipiani, K.; Petri, S.; Chen, J.; Calingasan, N. Y.; Beal, M. F. Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener. Dis., 2005, 2(5), 246-254.
157. Kawashima, D.; Asai, M.; Katagiri, K.; Takeuchi, R.; Ohtsuka, K. Reinvestigation of the effect of carbenoxolone on the induction of heat shock proteins. Cell Stress Chaperones., 2009, 14(5), 535-543.
158. Rossi, A.; Elia, G.; Santoro, M. G. 2-Cyclopenten-1-one, a new inducer of heat shock protein 70 with antiviral activity. J. Biol. Chem., 1996, 271(50), 32192-32196.
159. House, S. D.; Guidon, P. T., Jr.; Perdrizet, G. A.; Rewinski, M.; Kyriakos, R.; Bockman, R. S.; Mistry, T.; Gallagher, R. A.; High-tower, L. E. Effects of heat shock, stannous chloride, and gallium nitrate on the rat inflammatory response. Cell Stress Chaperones, 2001, 6(2), 164-171.
160. Hahm, K. B.; Park, I. S.; Kim, Y. S.; Kim, J. H.; Cho, S. W.; Lee, S. I.; Youn, J. K. Role of rebamipide on induction of heat-shock proteins and protection against reactive oxygen metabolite-mediated cell damage in cultured gastric mucosal cells. Free Radic. Biol. Med., 1997, 22(4), 711-716.
161. Odashima, M.; Otaka, M.; Jin, M.; Konishi, N.; Sato, T.; Kato, S.; Matsuhashi, T.; Nakamura, C.; Watanabe, S. Induction of a 72-kDa heat-shock protein in cultured rat gastric mucosal cells and rat gastric mucosa by zinc L-carnosine. Dig. Dis. Sci., 2002, 47(12), 2799-2804.
162. Hamel, L.; Kenney, M.; Jayyosi, Z.; Ardati, A.; Clark, K.; Spada, A.; Zilberstein, A.; Perrone, M.; Kaplow, J.; Merkel, L.; Rojas, C. Induction of heat shock protein 70 by herbimycin A and cyclopentenone prostaglandins in smooth muscle cells. Cell Stress Chaperone., 2000, 5(2), 121-131.
163. Rossi, A.; Elia, G.; Santoro, M. G. Activation of the heat shock factor 1 by serine protease inhibitors. An effect associated with nuclear factor-kappaB inhibition. J. Biol. Chem., 1998, 273(26), 16446-16452.
164. Wang, Q.; Mosser, D. D.; Bag, J. Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells. Hum. Mol. Genet., 2005, 14(23), 3673-3684.
165. Bhat, K. P. L.; Kosmeder, J. W.; Pezzuto, J. M. Biological effects of resveratrol. Antioxid. Redox Signal., 2001, 3(6), 1041-1064.
166. Parker, J. A.; Arango, M.; Abderrahmane, S.; Lambert, E.; Tourette, C.; Catoire, H.; Neri, C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet., 2005, 37(4), 349-350.
167. Putics, A.; Vegh, E. M.; Csermely, P.; Soti, C. Resveratrol induces the heat-shock response and protects human cells from severe heat stress. Antioxid. Redox Signal., 2008, 10(1), 65-75.
168. Westerheide, S. D.; Anckar, J.; Stevens, S. M., Jr.; Sistonen, L.; Morimoto, R. I. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science, 2009, 323(5917), 1063-1066.
169. Sittler, A.; Lurz, R.; Lueder, G.; Priller, J.; Lehrach, H.; Hayer-Hartl, M. K.; Hartl, F. U.; Wanker, E. E. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet., 2001, 10(12), 1307-1315.
170. Dou, F.; Netzer, W. J.; Tanemura, K.; Li, F.; Hartl, F. U.; Takashima, A.; Gouras, G. K.; Greengard, P. Xu, H. Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. USA, 2003, 100(2), 721-726.
171. Carmichael, J.; Chatellier, J.; Woolfson, A.; Milstein, C.; Fersht, A. R.; Rubinsztein, D. C. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc. Natl. Acad. Sci. USA, 2000, 97(17), 9701-9705.
172. Vacher, C.; Garcia-Oroz, L.; Rubinsztein, D. C. Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Hum. Mol. Genet., 2005, 14(22), 3425-3433.
173. Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 1994, 91(18), 8324-8328.
174. Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.; Toft, D.; Neckers, L. M. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones., 1998, 3(2), 100-108.
175. Yu, X.; Guo, Z. S.; Marcu, M. G.; Neckers, L.; Nguyen, D. M.; Chen, G. A.; Schrump, D. S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst., 2002, 94(7), 504-513.
176. Agrawal, N.; Pallos, J.; Slepko, N.; Apostol, B. L.; Bodai, L.; Chang, L. W.; Chiang, A. S.; Thompson, L. M.; Marsh, J. L. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl. Acad. Sci. USA, 2005, 102(10), 3777-3781.
177. Fujikake, N.; Nagai, Y.; Popiel, H. A.; Okamoto, Y.; Yamaguchi, M.; Toda, T. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J. Biol. Chem., 2008, 283(38), 26188-26197.
178. Yang, Z. Q.; Geng, X.; Solit, D.; Pratilas, C. A.; Rosen, N.; Danishefsky, S. J. New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target. J. Am. Chem. Soc., 2004, 126(25), 7881-7889.
179. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol., 2001, 8(3), 289-299.
180. Kreusch, A.; Han, S.; Brinker, A.; Zhou, V.; Choi, H. S.; He, Y.; Lesley, S. A.; Caldwell, J.; Gu, X. J. Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles. Bioorg. Med. Chem. Lett., 2005, 15(5), 1475-1478.
181. Suzuki, M.; Shinohara, F.; Endo, M.; Sugazaki, M.; Echigo, S.; Rikiishi, H. Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells. Cancer Chemother. Pharmacol., 2009, 64(2), 223-232.
182. DeBoer, C.; Meulman, P. A.; Wnuk, R. J.; Peterson, D. H. Geldanamycin, a new antibiotic. J. Antibiot. (Tokyo), 1970, 23(9), 442-447.
183. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem., 1999, 42(2), 260-266.
184. Soga, S.; Neckers, L. M.; Schulte, T. W.; Shiotsu, Y.; Akasaka, K.; Narumi, H.; Agatsuma, T.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Akinaga, S. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res., 1999, 59(12), 2931-2938.
185. Prodromou, C.; Roe, S. M.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell, 1997, 90(1), 65-75.
186. Akbar, D. H.; Al-Ghamdi, A. A. Is hypertension well controlled in hypertensive diabetics. Saudi Med. J., 2003, 24(4), 356-360.
187. Chen, M.; Ona, V. O.; Li, M.; Ferrante, R. J.; Fink, K. B.; Zhu, S.; Bian, J.; Guo, L.; Farrell, L. A.; Hersch, S. M.; Hobbs, W.; Vonsattel, J. P.; Cha, J. H.; Friedlander, R. M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med., 2000, 6(7), 797-801.
188. Jana, N. R.; Tanaka, M.; Wang, G.; Nukina, N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet., 2000, 9(13), 2009-2018.
189. Xiao, N.; Callaway, C. W.; Lipinski, C. A.; Hicks, S. D.; DeFranco, D. B. Geldanamycin provides posttreatment protection against glutamate-induced oxidative toxicity in a mouse hippocampal cell line. J. Neurochem., 1999, 72(1), 95-101.
190. Lu, A.; Ran, R.; Parmentier-Batteur, S.; Nee, A.; Sharp, F. R. Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia. J. Neurochem., 2002, 81(2), 355-364.
191. Gerges, N. Z.; Tran, I. C.; Backos, D. S.; Harrell, J. M.; Chinkers, M.; Pratt, W. B.; Esteban, J. A. Independent functions of hsp90 in neurotransmitter release and in the continuous synaptic cycling of AMPA receptors. J. Neurosci., 2004, 24(20), 4758-4766.
192. Sano, M. Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons. Neuropharmacology, 2001, 40(7), 947-953.
193. Hay, D. G.; Sathasivam, K.; Tobaben, S.; Stahl, B.; Marber, M.; Mestril, R.; Mahal, A.; Smith, D. L.; Woodman, B.; Bates, G. P. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet., 2004, 13(13), 1389-1405.
194. Ouyang, Y. B.; Xu, L.; Giffard, R. G. Geldanamycin treatment reduces delayed CA1 damage in mouse hippocampal organotypic cultures subjected to oxygen glucose deprivation. Neurosci. Lett., 2005, 380(3), 229-233.
195. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 2003, 425(6956), 407-410.
196. Mimnaugh, E. G.; Chavany, C.; Neckers, L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem., 1996, 271(37), 22796-22801.
197. Bonvini, P.; Dalla Rosa, H.; Vignes, N.; Rosolen, A. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res., 2004, 64(9), 3256-3264.
198. Flaherty, D. B.; Soria, J. P.; Tomasiewicz, H. G.; Wood, J. G. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J. Neurosci. Res., 2000, 62(3), 463-472.
199. Yamaguchi, H.; Ishiguro, K.; Uchida, T.; Takashima, A.; Lemere, C. A.; Imahori, K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol., 1996, 92(3), 232-241.
200. Peineau, S.; Bradley, C.; Taghibiglou, C.; Doherty, A.; Bortolotto, Z. A.; Wang, Y. T.; Collingridge, G. L. The role of GSK-3 in synaptic plasticity. Br. J. Pharmacol., 2008, 153, (Suppl 1), S428-437.
201. Angelo, M.; Plattner, F.; Giese, K. P. Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. J. Neurochem., 2006, 99(2), 353-370.
202. Luo, W.; Dou, F.; Rodina, A.; Chip, S.; Kim, J.; Zhao, Q.; Moulick, K.; Aguirre, J.; Wu, N.; Greengard, P.; Chiosis, G. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc. Natl. Acad. Sci. USA, 2007, 104(22), 9511-9516.
203. Dompierre, J. P.; Godin, J. D.; Charrin, B. C.; Cordelieres, F. P.; King, S. J.; Humbert, S.; Saudou, F. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci., 2007, 27(13), 3571-3583.
204. 2+ handling in Hunting ton's disease striatal cells: effect of histone deacetylase inhibitors. J. Neurosci., 2006, 26(43), 11174-11186.
205. Steffan, J. S.; Bodai, L.; Pallos, J.; Poelman, M.; McCampbell, A.; Apostol, B. L.; Kazantsev, A.; Schmidt, E.; Zhu, Y. Z.; Greenwald, M.; Kurokawa, R.; Housman, D. E.; Jackson, G. R.; Marsh, J. L.; Thompson, L. M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature, 2001, 413(6857), 739-743.
206. Ansar, S.; Burlison, J. A.; Hadden, M. K.; Yu, X. M.; Desino, K. E.; Bean, J.; Neckers, L.; Audus, K. L.; Michaelis, M. L.; Blagg, B. S. A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorg. Med. Chem. Lett., 2007, 17(7), 1984-1990.
207. Lu, Y.; Ansar, S.; Michaelis, M. L.; Blagg, B. S. Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line. Bioorg. Med. Chem., 2009, 17(4), 1709-1715.
208. Moriwaki, Y.; Kim, Y. J.; Ido, Y.; Misawa, H.; Kawashima, K.; Endo, S.; Takahashi, R. L347P PINK1 mutant that fails to bind to Hsp90/Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner. Neurosci. Res., 2008, 61(1), 43-48.
209. Bagatell, R.; Whitesell, L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther., 2004, 3(8), 1021-1030.
210. Alsbury, S.; Papageorgiou, K.; Latchman, D. S. Heat shock proteins can protect aged human and rodent cells from different stressful stimuli. Mech. Ageing Dev., 2004, 125(3), 201-209.
211. Schulman, D.; Latchman, D. S.; Yellon, D. M. Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2001, 281(4), H1630-1636.
212. Kregel, K. C.; Moseley, P. L.; Skidmore, R.; Gutierrez, J. A.; Guerriero, V. HSP70 accumulation in tissues of heat-stressed rats is blunted with advancing age. J. Appl. Physiol., 1995, 79(5), 1673-1678.
213. Nitta, Y.; Abe, K.; Aoki, M.; Ohno, I.; Isoyama, S. Diminished heat shock protein 70 mRNA induction in aged rat hearts after ischemia. Am. J. Physiol., 1994, 267(5 Pt 2), H1795-1803.
214. Morimoto, R. I. Stress, aging, and neurodegenerative disease. N. Engl. J. Med., 2006, 355(21), 2254-2255.
215. Seo, J. S.; Park, Y. M.; Kim, J. I.; Shim, E. H.; Kim, C. W.; Jang, J. J.; Kim, S. H.; Lee, W. H. T cell lymphoma in transgenic mice expressing the human Hsp70 gene. Biochem. Biophys. Res. Commun., 1996, 218(2), 582-587.
216. Cudkowicz, M. E.; Shefner, J. M.; Simpson, E.; Grasso, D.; Yu, H.; Zhang, H.; Shui, A.; Schoenfeld, D.; Brown, R. H.; Wieland, S.; Barber, J. R. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve, 2008, 38(1), 837-844.
217. Sanbe, A.; Daicho, T.; Mizutani, R.; Endo, T.; Miyauchi, N.; Yamauchi, J.; Tanonaka, K.; Glabe, C.; Tanoue, A. Protective effect of geranylgeranylacetone via enhancement of HSPB8 induction in desmin-related cardiomyopathy. PLoS One, 2009, 4(4), e5351.
218. Akiyama, S.; Chen, Z. S.; Sumizawa, T.; Furukawa, T. Resistance to cisplatin. Anticancer Drug Des., 1999, 14(2), 143-151.
219. Hamers, F. P.; Brakkee, J. H.; Cavalletti, E.; Tedeschi, M.; Marmonti, L.; Pezzoni, G.; Neijt, J. P.; Gispen, W. H. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res., 1993, 53(3), 544-549.
220. Blachley, J. D.; Hill, J. B. Renal and electrolyte disturbances associated with cisplatin. Ann. Intern. Med., 1981, 95(5), 628-632.
221. Basu, R.; Rajkumar, A.; Datta, N. R. Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int. J. Clin. Oncol., 2002, 7(6), 365-367.
222. Ramesh, G.; Reeves, W. B. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am. J. Physiol. Renal Physiol., 2005, 289(1), F166-174.
223. Zhang, L.; Cooper, A. J.; Krasnikov, B. F.; Xu, H.; Bubber, P.; Pinto, J. T.; Gibson, G. E.; Hanigan, M. H. Cisplatin-induced toxicity is associated with platinum deposition in mouse kidney mitochondria in vivo and with selective inactivation of the alpha-ketoglutarate dehydrogenase complex in LLC-PK1 cells. Biochemistry, 2006, 45(29), 8959-8971.
224. Li, G.; Liu, W.; Frenz, D. Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS. Neurotoxicology, 2006, 27(1), 22-30.
225. El-Makawy, A. I.; Girgis, S. M.; Khalil, W. K. Developmental and genetic toxicity of stannous chloride in mouse dams and fetuses. Mutat. Res., 2008, 657(2), 105-110.
226. Gyori, J.; Platoshyn, O.; Carpenter, D. O.; Salanki, J. Effect of inorganic and organic tin compounds on ACh- and voltage-activated Na currents. Cell. Mol. Neurobiol., 2000, 20(5), 591-604.
227. Silva, C. R.; Oliveira, M. B.; Melo, S. F.; Dantas, F. J.; de Mattos, J. C.; Bezerra, R. J.; Caldeira-de-Araujo, A.; Duatti, A.; Bernardo-Filho, M. Biological effects of stannous chloride, a substance that can produce stimulation or depression of the central nervous system. Brain Res. Bull., 2002, 59(3), 213-216.
228. Dantas, F. J.; Moraes, M. O.; de Mattos, J. C.; Bezerra, R. J.; Carvalho, E. F.; Filho, M. B.; Caldeira de Araujo, A. Stannous chloride mediates single strand breaks in plasmid DNA through reactive oxygen species formation. Toxicol. Lett., 1999, 110(3), 129-136.
229. Dantas, F. J.; de Mattos, J. C.; Moraes, M. O.; Viana, M. E.; Lage, C. A.; Cabral-Neto, J. B.; Leitao, A. C.; Bernardo-Filho, M.; Bezerraa, R. J.; Carvalho, J. J.; Caldeira-de-Araujo, A. Genotoxic effects of stannous chloride (SnCl2) in K562 cell line. Food Chem. Toxicol., 2002, 40(10), 1493-1498.
230. Tomaszewski, A.; Busselberg, D. SnCl(2) reduces voltage-activated calcium channel currents of dorsal root ganglion neurons of rats. Neurotoxicology, 2008, 29(6), 958-963.
231. Neckers, L. Heat shock protein 90: the cancer chaperone. J. Biosci., 2007, 32(3), 517-530.
232. Shimamura, T.; Shapiro, G. I. Heat shock protein 90 inhibition in lung cancer. J. Thorac. Oncol., 2008, 3(6 Suppl 2), S152-159.
233. Solit, D. B.; Ivy, S. P.; Kopil, C.; Sikorski, R.; Morris, M. J.; Slovin, S. F.; Kelly, W. K.; DeLaCruz, A.; Curley, T.; Heller, G.; Larson, S.; Schwartz, L.; Egorin, M. J.; Rosen, N.; Scher, H. I. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res., 2007, 13(6), 1775-1782.
234. Olaharski, A. J.; Ji, Z.; Woo, J. Y.; Lim, S.; Hubbard, A. E.; Zhang, L.; Smith, M. T. The histone deacetylase inhibitor trichostatin a has genotoxic effects in human lymphoblasts in vitro. Toxicol. Sci., 2006, 93(2), 341-347.
235. Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H.; Rosen, N.; Spampinato, C.; Modrich, P.; Chiosis, G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol., 2004, 11(6), 787-797.
236. Alcazar, A.; Cid, C. High cytotoxic sensitivity of the oligodendrocyte precursor cells to HSP90 inhibitors in cell cultures. Exp. Neurol., 2009, 216(2), 511-514.
237. Fink, S. L.; Chang, L. K.; Ho, D. Y.; Sapolsky, R. M. Defective herpes simplex virus vectors expressing the rat brain stress-inducible heat shock protein 72 protect cultured neurons from severe heat shock. J. Neurochem., 1997, 68(3), 961-969.
238. Wagstaff, M. J.; Collaco-Moraes, Y.; Smith, J.; de Belleroche, J. S.; Coffin, R. S.; Latchman, D. S. Protection of neuronal cells from apoptosis by Hsp27 delivered with a herpes simplex virus-based vector. J. Biol. Chem., 1999, 274(8), 5061-5069.
239. Akbar, M. T.; Lundberg, A. M.; Liu, K.; Vidyadaran, S.; Wells, K. E.; Dolatshad, H.; Wynn, S.; Wells, D. J.; Latchman, D. S.; de Belleroche, J. The neuroprotective effects of heat shock protein 27 overexpression in transgenic animals against kainate-induced seizures and hippocampal cell death. J. Biol. Chem., 2003, 278(22), 19956-19965.
240. Perrin, V.; Regulier, E.; Abbas-Terki, T.; Hassig, R.; Brouillet, E.; Aebischer, P.; Luthi-Carter, R.; Deglon, N. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol. Ther., 2007, 15(5), 903-911.
241. Kalwy, S. A.; Akbar, M. T.; Coffin, R. S.; de Belleroche, J.; Latchman, D. S. Heat shock protein 27 delivered via a herpes simplex virus vector can protect neurons of the hippocampus against kainic-acid-induced cell loss. Brain Res. Mol. Brain Res., 2003, 111(1-2), 91-103.
242. Williams, A. J.; Knutson, T. M.; Colomer Gould, V. F.; Paulson, H. L. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol. Dis., 2009, 33(3), 342-353.
243. Sawkar, A. R.; Cheng, W. C.; Beutler, E.; Wong, C. H.; Balch, W. E.; Kelly, J. W. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. USA, 2002, 99(24), 15428-15433.
244. Chow, A. M.; Brown, I. R. Induction of heat shock proteins in differentiated human and rodent neurons by celastrol. Cell Stress Chaperones., 2007, 12(3), 237-244.
245. Ohta, H.; Matsumoto, K.; Watanabe, H.; Shimizu, M. Involvement of beta-adrenergic systems in the antagonizing effect of paeoniflorin on the scopolamine-induced deficit in radial maze performance in rats. Jpn. J. Pharmacol., 1993, 62(4), 345-349.